Synovial Fluid Sleep Study

Sponsor
NYU Langone Health (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04688099
Collaborator
(none)
60
1
34.1
1.8

Study Details

Study Description

Brief Summary

This is an observational study of the relationship between perioperative sleep time/quality, synovial fluid cytokine profiles, and clinical outcomes of primary ACL reconstruction with BPTB autograft in 50 subjects. Sleep during the week before and month after surgery will be assessed using Fitbit smartwatch and sleep diary. Synovial fluid sampled preoperatively, intraoperatively, and postoperatively will be analyzed for levels of pro- and anti-inflammatory cytokines. Postoperative knee pain and function will be assessed until 2 years post-op using validated questionnaires.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Single-center Observational Study of the Relationship Between Sleep, Synovial Fluid Cytokine Profiles, & Outcomes of ACL Reconstruction
    Actual Study Start Date :
    Sep 27, 2021
    Anticipated Primary Completion Date :
    Aug 1, 2024
    Anticipated Study Completion Date :
    Aug 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Knee injury and Osteoarthritis Outcome Score (KOOS) [Year 2]

      KOOS is a survey is meant to track how the participant feels about their knee and how well they are able to perform their usual activities. There are six categories in the survey: Symptoms, Stiffness, Pain, Function/Daily Living, Function/Sports, Quality of Life. Symptoms category consists of 5 questions, ranked from "never" to "always" (0-5). Stiffness category consists of 2 questions, ranked from "none" to "extreme" (0-5). Pain category consists of 9 questions, ranked from "none" to "extreme" (0-5). Function/Daily Living category consists of 17 questions, ranked from "none" to "extreme" (0-5). Function/Sports category consists of 5 questions, ranked from "none" to "extreme" (0-5). Quality of Life category consists of 4 questions, ranked from "not at all" to "extremely, constantly, totally" (0-5). The total range of score is 0-210. The lower the score, the better they feel about their knee and performance of usual activities.

    Secondary Outcome Measures

    1. Score on Lysholm Knee Scoring Scale [Year 2]

      The Lysholm Knee Scoring Scale consists of 35 common complaints which people frequently have with their knee problems. Participants will check each statement which best describes their condition -- each statement is assigned a particular score, and those scores are added together to obtain the total score out of 100 (total range: 0-100). A higher score indicates more knee problems.

    2. VAS Score for Anterior Knee Pain [Year 2]

      The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain." The total score range is 0-10; the higher the score, the worse the pain.

    3. Knee Range of Motion [Year 1]

      Knee range of motion (maximal flexion and extension) will be measured bilaterally using a goniometer.

    4. Thigh Circumference [Year 1]

      Thigh circumference will be measured bilaterally.

    5. Concentration of Synovial Fluid Cytokines [Year 1]

      Synovial fluid from the injured knee will be sampled preoperatively, intraoperatively, and postoperatively and analyzed for levels of the following pro- and anti-inflammatory cytokines using multiplex magnetic bead immunoassay or ELISA: matrix metalloproteinase (MMP) 3, tissue inhibitor of metalloproteinase (TIMP) 1, TIMP-2, interleukin-1 receptor antagonist (IL-1ra), IL-6, monocyte chemotactic protein (MCP) 1, macrophage inflammatory protein (MIP) 1beta/CCL4, RANTES (regulated upon activation, normal T cell expressed and secreted), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF/FGF-2).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. At least 18 years of age

    2. Undergoing primary ACL reconstruction with BPTB autograft for acute ACL tear, with or without concomitant meniscectomy

    3. Presenting within 2 weeks of injury and undergoing reconstruction within 8 weeks of injury

    Exclusion Criteria:
    1. History of blood-borne diseases including HIV, HBV, HCV, HTLV, or syphilis

    2. Pregnant

    3. Multiligamentous knee injury

    4. Concomitant meniscal repair, meniscal allograft transplantation, osteotomy, or repair of focal chondral defect (e.g., osteochondral autograft transfer system, osteochondral allograft, matrix-induced autologous chondrocyte implantation)

    5. Prior ipsilateral knee surgeries or injuries

    6. Primary sleep disorders including insomnia, sleep apnea, or restless legs syndrome

    7. Uncontrolled psychiatric disorders with sleep disturbance

    8. Night shift work

    9. Travel with time zone change within three weeks of surgery

    10. Systemic inflammatory disease

    11. Autoimmune disease

    12. Immunomodulatory drug use

    13. Chemotherapy within a year before surgery

    14. Intra-articular injection within 3 months before surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Langone Health New York New York United States 10003

    Sponsors and Collaborators

    • NYU Langone Health

    Investigators

    • Principal Investigator: Eric Strauss, MD, NYU Langone Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NYU Langone Health
    ClinicalTrials.gov Identifier:
    NCT04688099
    Other Study ID Numbers:
    • 20-01872
    First Posted:
    Dec 29, 2020
    Last Update Posted:
    Aug 3, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 3, 2022